CIMAB SA is a Cuban company, dedicated to the development and administration of business through its direct participation in international alliances involving the main biotechnological products of CIM.
IncuBIO has been designed for the special purpose of attracting venture capital. Prospective investors will have the opportunity to acquire shares of IncuBIO and contribute to increasing the value of the products by funding concept-proof clinical trials in developed country markets.
To achieve this, IncuBIO has an exclusive license for the development and marketing of innovative biotechnology products, including NeuroEPO, one of the most promising assets in the portfolio of the Center for Molecular Immunology (CIM), A leading Cuban biotechnology company.
NeuroEPO is an intranasal formulation of recombinant human erythropoietin with low sialic acid content that is being clinically evaluated in Cuba for the treatment of various neurodegenerative diseases, such as Alzheimer’s, Parkinson’s and Ataxia.
During the recently completed concept test trial in Cuba, NeuroEPO showed evidence of acting as a homeostatic regulator of the brain, improving cognitive impairment in Alzheimer’s patients.
CIMAB SA is a Cuban company, dedicated to the development and administration of business through its direct participation in international alliances involving the main biotechnological products of CIM. With the incorporation of IncuBIO, CIMAB is now a shareholder in five joint ventures located in China, Thailand, Singapore and Cuba.
Neuronic Mexicana SA de CV is a Mexican company, established since 1996, dedicated to the marketing of biopharmaceuticals and medical equipment.
(With information from the Center for Molecular Immunology)